 | • レポートコード：QYR2104Z4166 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、134ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、糖尿病用非インスリン療法のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（アルファ-グルコシダーゼ阻害剤、アミリンアゴニスト、ビグアニド、ジペプチジルペプチダーゼ4（DPP4）阻害剤、グリニド/メグリチニド、GLP-1アナログ/ GLP-1アゴニスト、ナトリウム-グルコース共輸送体2（SGLT2）阻害剤、スルホニル尿素、チアゾリジンジオン）、用途別市場規模（モニタリング、診断、治療、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・糖尿病用非インスリン療法の市場動向 ・企業の競争状況、市場シェア ・糖尿病用非インスリン療法の種類別市場規模（アルファ-グルコシダーゼ阻害剤、アミリンアゴニスト、ビグアニド、ジペプチジルペプチダーゼ4（DPP4）阻害剤、グリニド/メグリチニド、GLP-1アナログ/ GLP-1アゴニスト、ナトリウム-グルコース共輸送体2（SGLT2）阻害剤、スルホニル尿素、チアゾリジンジオン） ・糖尿病用非インスリン療法の用途別市場規模（モニタリング、診断、治療、その他） ・糖尿病用非インスリン療法の北米市場規模2016-2027（アメリカ、カナダ） ・糖尿病用非インスリン療法のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・糖尿病用非インスリン療法のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・糖尿病用非インスリン療法の中南米市場規模2016-2027（メキシコ、ブラジル） ・糖尿病用非インスリン療法の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（GSK、Eli Lilly、Sumitomo Dainippon Pharma、Intarcia Therapeutics、Servier、Pfizer、Merck、Dong-A Pharmaceutical、Luye Pharma Group、Eurofarma、Geropharm、Alkem Labs、SatRx、Jiangsu Hansoh Pharmaceutical、Novo Nordisk、Emisphere、Uni-Bio Science Group、Takeda、3SBio、Jiangsu Hengrui Medicine） ・結論 |
Market Analysis and Insights: Global Non-Insulin Therapies for Diabetes Market
The global Non-Insulin Therapies for Diabetes market size is projected to reach US$ 54930 million by 2026, from US$ 30040 million in 2019, at a CAGR of 8.9% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Non-Insulin Therapies for Diabetes market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Non-Insulin Therapies for Diabetes market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Non-Insulin Therapies for Diabetes market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Non-Insulin Therapies for Diabetes market.
Global Non-Insulin Therapies for Diabetes Scope and Market Size
Non-Insulin Therapies for Diabetes market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Non-Insulin Therapies for Diabetes market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Alpha-glucosidase Inhibitors
Amylin Agonists
Biguanides
Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Glinides / Meglitinides
GLP-1 Analogs / GLP-1 Agonists
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Sulfonylureas
Thiazolidinediones
Others
Segment by Application
Monitoring
Diagnosis
Treatment
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
GSK
Eli Lilly
Sumitomo Dainippon Pharma
Intarcia Therapeutics
Servier
Pfizer
Merck
Dong-A Pharmaceutical
Luye Pharma Group
Intarcia Therapeutics
Servier
Alkem Labs
SatRx
Jiangsu Hansoh Pharmaceutical
Novo Nordisk
Emisphere
Uni-Bio Science Group
Takeda
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Alpha-glucosidase Inhibitors
1.2.3 Amylin Agonists
1.2.4 Biguanides
1.2.5 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
1.2.6 Glinides / Meglitinides
1.2.7 GLP-1 Analogs / GLP-1 Agonists
1.2.8 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
1.2.9 Sulfonylureas
1.2.10 Thiazolidinediones
1.2.11 Others
1.3 Market by Application
1.3.1 Global Non-Insulin Therapies for Diabetes Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Monitoring
1.3.3 Diagnosis
1.3.4 Treatment
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Non-Insulin Therapies for Diabetes Market Perspective (2016-2027)
2.2 Non-Insulin Therapies for Diabetes Growth Trends by Regions
2.2.1 Non-Insulin Therapies for Diabetes Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Non-Insulin Therapies for Diabetes Historic Market Share by Regions (2016-2021)
2.2.3 Non-Insulin Therapies for Diabetes Forecasted Market Size by Regions (2022-2027)
2.3 Non-Insulin Therapies for Diabetes Industry Dynamic
2.3.1 Non-Insulin Therapies for Diabetes Market Trends
2.3.2 Non-Insulin Therapies for Diabetes Market Drivers
2.3.3 Non-Insulin Therapies for Diabetes Market Challenges
2.3.4 Non-Insulin Therapies for Diabetes Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Insulin Therapies for Diabetes Players by Revenue
3.1.1 Global Top Non-Insulin Therapies for Diabetes Players by Revenue (2016-2021)
3.1.2 Global Non-Insulin Therapies for Diabetes Revenue Market Share by Players (2016-2021)
3.2 Global Non-Insulin Therapies for Diabetes Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Non-Insulin Therapies for Diabetes Revenue
3.4 Global Non-Insulin Therapies for Diabetes Market Concentration Ratio
3.4.1 Global Non-Insulin Therapies for Diabetes Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Insulin Therapies for Diabetes Revenue in 2020
3.5 Non-Insulin Therapies for Diabetes Key Players Head office and Area Served
3.6 Key Players Non-Insulin Therapies for Diabetes Product Solution and Service
3.7 Date of Enter into Non-Insulin Therapies for Diabetes Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Insulin Therapies for Diabetes Breakdown Data by Type
4.1 Global Non-Insulin Therapies for Diabetes Historic Market Size by Type (2016-2021)
4.2 Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Type (2022-2027)
5 Non-Insulin Therapies for Diabetes Breakdown Data by Application
5.1 Global Non-Insulin Therapies for Diabetes Historic Market Size by Application (2016-2021)
5.2 Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Non-Insulin Therapies for Diabetes Market Size (2016-2027)
6.2 North America Non-Insulin Therapies for Diabetes Market Size by Type
6.2.1 North America Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021)
6.2.2 North America Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027)
6.2.3 North America Non-Insulin Therapies for Diabetes Market Size by Type (2016-2027)
6.3 North America Non-Insulin Therapies for Diabetes Market Size by Application
6.3.1 North America Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021)
6.3.2 North America Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027)
6.3.3 North America Non-Insulin Therapies for Diabetes Market Size by Application (2016-2027)
6.4 North America Non-Insulin Therapies for Diabetes Market Size by Country
6.4.1 North America Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021)
6.4.2 North America Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Non-Insulin Therapies for Diabetes Market Size (2016-2027)
7.2 Europe Non-Insulin Therapies for Diabetes Market Size by Type
7.2.1 Europe Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021)
7.2.2 Europe Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027)
7.2.3 Europe Non-Insulin Therapies for Diabetes Market Size by Type (2016-2027)
7.3 Europe Non-Insulin Therapies for Diabetes Market Size by Application
7.3.1 Europe Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021)
7.3.2 Europe Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027)
7.3.3 Europe Non-Insulin Therapies for Diabetes Market Size by Application (2016-2027)
7.4 Europe Non-Insulin Therapies for Diabetes Market Size by Country
7.4.1 Europe Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021)
7.4.2 Europe Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size (2016-2027)
8.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type
8.2.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type (2016-2027)
8.3 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application
8.3.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application (2016-2027)
8.4 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region
8.4.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Non-Insulin Therapies for Diabetes Market Size (2016-2027)
9.2 Latin America Non-Insulin Therapies for Diabetes Market Size by Type
9.2.1 Latin America Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021)
9.2.2 Latin America Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027)
9.2.3 Latin America Non-Insulin Therapies for Diabetes Market Size by Type (2016-2027)
9.3 Latin America Non-Insulin Therapies for Diabetes Market Size by Application
9.3.1 Latin America Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021)
9.3.2 Latin America Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027)
9.3.3 Latin America Non-Insulin Therapies for Diabetes Market Size by Application (2016-2027)
9.4 Latin America Non-Insulin Therapies for Diabetes Market Size by Country
9.4.1 Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021)
9.4.2 Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size (2016-2027)
10.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type
10.2.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type (2016-2027)
10.3 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application
10.3.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application (2016-2027)
10.4 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country
10.4.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Non-Insulin Therapies for Diabetes Introduction
11.1.4 GSK Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.1.5 GSK Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Introduction
11.2.4 Eli Lilly Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.2.5 Eli Lilly Recent Development
11.3 Sumitomo Dainippon Pharma
11.3.1 Sumitomo Dainippon Pharma Company Details
11.3.2 Sumitomo Dainippon Pharma Business Overview
11.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Introduction
11.3.4 Sumitomo Dainippon Pharma Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.3.5 Sumitomo Dainippon Pharma Recent Development
11.4 Intarcia Therapeutics
11.4.1 Intarcia Therapeutics Company Details
11.4.2 Intarcia Therapeutics Business Overview
11.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Introduction
11.4.4 Intarcia Therapeutics Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.4.5 Intarcia Therapeutics Recent Development
11.5 Servier
11.5.1 Servier Company Details
11.5.2 Servier Business Overview
11.5.3 Servier Non-Insulin Therapies for Diabetes Introduction
11.5.4 Servier Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.5.5 Servier Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Non-Insulin Therapies for Diabetes Introduction
11.6.4 Pfizer Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.6.5 Pfizer Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Non-Insulin Therapies for Diabetes Introduction
11.7.4 Merck Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.7.5 Merck Recent Development
11.8 Dong-A Pharmaceutical
11.8.1 Dong-A Pharmaceutical Company Details
11.8.2 Dong-A Pharmaceutical Business Overview
11.8.3 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Introduction
11.8.4 Dong-A Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.8.5 Dong-A Pharmaceutical Recent Development
11.9 Luye Pharma Group
11.9.1 Luye Pharma Group Company Details
11.9.2 Luye Pharma Group Business Overview
11.9.3 Luye Pharma Group Non-Insulin Therapies for Diabetes Introduction
11.9.4 Luye Pharma Group Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.9.5 Luye Pharma Group Recent Development
11.10 Eurofarma
11.10.1 Eurofarma Company Details
11.10.2 Eurofarma Business Overview
11.10.3 Eurofarma Non-Insulin Therapies for Diabetes Introduction
11.10.4 Eurofarma Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.10.5 Eurofarma Recent Development
11.11 Geropharm
11.11.1 Geropharm Company Details
11.11.2 Geropharm Business Overview
11.11.3 Geropharm Non-Insulin Therapies for Diabetes Introduction
11.11.4 Geropharm Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.11.5 Geropharm Recent Development
11.12 Alkem Labs
11.12.1 Alkem Labs Company Details
11.12.2 Alkem Labs Business Overview
11.12.3 Alkem Labs Non-Insulin Therapies for Diabetes Introduction
11.12.4 Alkem Labs Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.12.5 Alkem Labs Recent Development
11.13 SatRx
11.13.1 SatRx Company Details
11.13.2 SatRx Business Overview
11.13.3 SatRx Non-Insulin Therapies for Diabetes Introduction
11.13.4 SatRx Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.13.5 SatRx Recent Development
11.14 Jiangsu Hansoh Pharmaceutical
11.14.1 Jiangsu Hansoh Pharmaceutical Company Details
11.14.2 Jiangsu Hansoh Pharmaceutical Business Overview
11.14.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Introduction
11.14.4 Jiangsu Hansoh Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.14.5 Jiangsu Hansoh Pharmaceutical Recent Development
11.15 Novo Nordisk
11.15.1 Novo Nordisk Company Details
11.15.2 Novo Nordisk Business Overview
11.15.3 Novo Nordisk Non-Insulin Therapies for Diabetes Introduction
11.15.4 Novo Nordisk Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.15.5 Novo Nordisk Recent Development
11.16 Emisphere
11.16.1 Emisphere Company Details
11.16.2 Emisphere Business Overview
11.16.3 Emisphere Non-Insulin Therapies for Diabetes Introduction
11.16.4 Emisphere Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.16.5 Emisphere Recent Development
11.17 Uni-Bio Science Group
11.17.1 Uni-Bio Science Group Company Details
11.17.2 Uni-Bio Science Group Business Overview
11.17.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Introduction
11.17.4 Uni-Bio Science Group Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.17.5 Uni-Bio Science Group Recent Development
11.18 Takeda
11.18.1 Takeda Company Details
11.18.2 Takeda Business Overview
11.18.3 Takeda Non-Insulin Therapies for Diabetes Introduction
11.18.4 Takeda Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.18.5 Takeda Recent Development
11.18 3SBio
.1 3SBio Company Details
.2 3SBio Business Overview
.3 3SBio Non-Insulin Therapies for Diabetes Introduction
.4 3SBio Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
.5 3SBio Recent Development
11.20 Jiangsu Hengrui Medicine
11.20.1 Jiangsu Hengrui Medicine Company Details
11.20.2 Jiangsu Hengrui Medicine Business Overview
11.20.3 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Introduction
11.20.4 Jiangsu Hengrui Medicine Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021)
11.20.5 Jiangsu Hengrui Medicine Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Alpha-glucosidase Inhibitors
Table 3. Key Players of Amylin Agonists
Table 4. Key Players of Biguanides
Table 5. Key Players of Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Table 6. Key Players of Glinides / Meglitinides
Table 7. Key Players of GLP-1 Analogs / GLP-1 Agonists
Table 8. Key Players of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Table 9. Key Players of Sulfonylureas
Table 10. Key Players of Thiazolidinediones
Table 11. Key Players of Others
Table 12. Global Non-Insulin Therapies for Diabetes Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 13. Global Non-Insulin Therapies for Diabetes Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 14. Global Non-Insulin Therapies for Diabetes Market Size by Regions (2016-2021) & (US$ Million)
Table 15. Global Non-Insulin Therapies for Diabetes Market Share by Regions (2016-2021)
Table 16. Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 17. Global Non-Insulin Therapies for Diabetes Market Share by Regions (2022-2027)
Table 18. Non-Insulin Therapies for Diabetes Market Trends
Table 19. Non-Insulin Therapies for Diabetes Market Drivers
Table 20. Non-Insulin Therapies for Diabetes Market Challenges
Table 21. Non-Insulin Therapies for Diabetes Market Restraints
Table 22. Global Non-Insulin Therapies for Diabetes Revenue by Players (2016-2021) & (US$ Million)
Table 23. Global Non-Insulin Therapies for Diabetes Market Share by Players (2016-2021)
Table 24. Global Top Non-Insulin Therapies for Diabetes Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Insulin Therapies for Diabetes as of 2020)
Table 25. Ranking of Global Top Non-Insulin Therapies for Diabetes Companies by Revenue (US$ Million) in 2020
Table 26. Global 5 Largest Players Market Share by Non-Insulin Therapies for Diabetes Revenue (CR5 and HHI) & (2016-2021)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Non-Insulin Therapies for Diabetes Product Solution and Service
Table 29. Date of Enter into Non-Insulin Therapies for Diabetes Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) (US$ Million)
Table 32. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type (2016-2021)
Table 33. Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 34. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 35. Global Non-Insulin Therapies for Diabetes Market Size Share by Application (2016-2021) & (US$ Million)
Table 36. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Application (2016-2021)
Table 37. Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 38. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 39. North America Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) (US$ Million)
Table 40. North America Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027) & (US$ Million)
Table 41. North America Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021) (US$ Million)
Table 42. North America Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027) & (US$ Million)
Table 43. North America Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021) & (US$ Million)
Table 44. North America Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027) & (US$ Million)
Table 45. Europe Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) (US$ Million)
Table 46. Europe Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027) & (US$ Million)
Table 47. Europe Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021) (US$ Million)
Table 48. Europe Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027) & (US$ Million)
Table 49. Europe Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021) & (US$ Million)
Table 50. Europe Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) (US$ Million)
Table 52. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027) & (US$ Million)
Table 53. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021) (US$ Million)
Table 54. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027) & (US$ Million)
Table 55. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2016-2021) & (US$ Million)
Table 56. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2022-2027) & (US$ Million)
Table 57. Latin America Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) (US$ Million)
Table 58. Latin America Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027) & (US$ Million)
Table 59. Latin America Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021) (US$ Million)
Table 60. Latin America Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027) & (US$ Million)
Table 61. Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021) & (US$ Million)
Table 62. Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) (US$ Million)
Table 64. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027) & (US$ Million)
Table 65. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021) (US$ Million)
Table 66. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027) & (US$ Million)
Table 67. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021) & (US$ Million)
Table 68. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027) & (US$ Million)
Table 69. GSK Company Details
Table 70. GSK Business Overview
Table 71. GSK Non-Insulin Therapies for Diabetes Product
Table 72. GSK Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 73. GSK Recent Development
Table 74. Eli Lilly Company Details
Table 75. Eli Lilly Business Overview
Table 76. Eli Lilly Non-Insulin Therapies for Diabetes Product
Table 77. Eli Lilly Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 78. Eli Lilly Recent Development
Table 79. Sumitomo Dainippon Pharma Company Details
Table 80. Sumitomo Dainippon Pharma Business Overview
Table 81. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Product
Table 82. Sumitomo Dainippon Pharma Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 83. Sumitomo Dainippon Pharma Recent Development
Table 84. Intarcia Therapeutics Company Details
Table 85. Intarcia Therapeutics Business Overview
Table 86. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Product
Table 87. Intarcia Therapeutics Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 88. Intarcia Therapeutics Recent Development
Table 89. Servier Company Details
Table 90. Servier Business Overview
Table 91. Servier Non-Insulin Therapies for Diabetes Product
Table 92. Servier Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 93. Servier Recent Development
Table 94. Pfizer Company Details
Table 95. Pfizer Business Overview
Table 96. Pfizer Non-Insulin Therapies for Diabetes Product
Table 97. Pfizer Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 98. Pfizer Recent Development
Table 99. Merck Company Details
Table 100. Merck Business Overview
Table 101. Merck Non-Insulin Therapies for Diabetes Product
Table 102. Merck Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 103. Merck Recent Development
Table 104. Dong-A Pharmaceutical Company Details
Table 105. Dong-A Pharmaceutical Business Overview
Table 106. Dong-A Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 107. Dong-A Pharmaceutical Recent Development
Table 108. Luye Pharma Group Company Details
Table 109. Luye Pharma Group Business Overview
Table 110. Luye Pharma Group Non-Insulin Therapies for Diabetes Product
Table 111. Luye Pharma Group Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 112. Luye Pharma Group Recent Development
Table 113. Eurofarma Company Details
Table 114. Eurofarma Business Overview
Table 115. Eurofarma Non-Insulin Therapies for Diabetes Product
Table 116. Eurofarma Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 117. Eurofarma Recent Development
Table 118. Geropharm Company Details
Table 119. Geropharm Business Overview
Table 120. Geropharm Non-Insulin Therapies for Diabetes Product
Table 121. Geropharm Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 122. Geropharm Recent Development
Table 123. Alkem Labs Company Details
Table 124. Alkem Labs Business Overview
Table 125. Alkem Labs Non-Insulin Therapies for Diabetes Product
Table 126. Alkem Labs Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 127. Alkem Labs Recent Development
Table 128. SatRx Company Details
Table 129. SatRx Business Overview
Table 130. SatRx Non-Insulin Therapies for Diabetes Product
Table 131. SatRx Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 132. SatRx Recent Development
Table 133. Jiangsu Hansoh Pharmaceutical Company Details
Table 134. Jiangsu Hansoh Pharmaceutical Business Overview
Table 135. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Product
Table 136. Jiangsu Hansoh Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 137. Jiangsu Hansoh Pharmaceutical Recent Development
Table 138. Novo Nordisk Company Details
Table 139. Novo Nordisk Business Overview
Table 140. Novo Nordisk Non-Insulin Therapies for Diabetes Product
Table 141. Novo Nordisk Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 142. Novo Nordisk Recent Development
Table 143. Emisphere Company Details
Table 144. Emisphere Business Overview
Table 145. Emisphere Non-Insulin Therapies for Diabetes Product
Table 146. Emisphere Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 147. Emisphere Recent Development
Table 148. Uni-Bio Science Group Company Details
Table 149. Uni-Bio Science Group Business Overview
Table 150. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Product
Table 151. Uni-Bio Science Group Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 152. Uni-Bio Science Group Recent Development
Table 153. Takeda Company Details
Table 154. Takeda Business Overview
Table 155. Takeda Non-Insulin Therapies for Diabetes Product
Table 156. Takeda Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 157. Takeda Recent Development
Table 158. 3SBio Company Details
Table 159. 3SBio Business Overview
Table 160. 3SBio Non-Insulin Therapies for Diabetes Product
Table 161. 3SBio Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 162. 3SBio Recent Development
Table 163. Jiangsu Hengrui Medicine Company Details
Table 164. Jiangsu Hengrui Medicine Business Overview
Table 165. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Product
Table 166. Jiangsu Hengrui Medicine Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million)
Table 167. Jiangsu Hengrui Medicine Recent Development
Table 168. Research Programs/Design for This Report
Table 169. Key Data Information from Secondary Sources
Table 170. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Insulin Therapies for Diabetes Market Share by Type: 2020 VS 2027
Figure 2. Alpha-glucosidase Inhibitors Features
Figure 3. Amylin Agonists Features
Figure 4. Biguanides Features
Figure 5. Dipeptidyl Peptidase-4 (DPP4) Inhibitors Features
Figure 6. Glinides / Meglitinides Features
Figure 7. GLP-1 Analogs / GLP-1 Agonists Features
Figure 8. Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Features
Figure 9. Sulfonylureas Features
Figure 10. Thiazolidinediones Features
Figure 11. Others Features
Figure 12. Global Non-Insulin Therapies for Diabetes Market Share by Application: 2020 VS 2027
Figure 13. Monitoring Case Studies
Figure 14. Diagnosis Case Studies
Figure 15. Treatment Case Studies
Figure 16. Others Case Studies
Figure 17. Non-Insulin Therapies for Diabetes Report Years Considered
Figure 18. Global Non-Insulin Therapies for Diabetes Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 19. Global Non-Insulin Therapies for Diabetes Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 20. Global Non-Insulin Therapies for Diabetes Market Share by Regions: 2020 VS 2027
Figure 21. Global Non-Insulin Therapies for Diabetes Market Share by Regions (2022-2027)
Figure 22. Global Non-Insulin Therapies for Diabetes Market Share by Players in 2020
Figure 23. Global Top Non-Insulin Therapies for Diabetes Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Insulin Therapies for Diabetes as of 2020
Figure 24. The Top 10 and 5 Players Market Share by Non-Insulin Therapies for Diabetes Revenue in 2020
Figure 25. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type (2016-2021)
Figure 26. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type (2022-2027)
Figure 27. North America Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. North America Non-Insulin Therapies for Diabetes Market Share by Type (2016-2027)
Figure 29. North America Non-Insulin Therapies for Diabetes Market Share by Application (2016-2027)
Figure 30. North America Non-Insulin Therapies for Diabetes Market Share by Country (2016-2027)
Figure 31. United States Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Canada Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Europe Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Europe Non-Insulin Therapies for Diabetes Market Share by Type (2016-2027)
Figure 35. Europe Non-Insulin Therapies for Diabetes Market Share by Application (2016-2027)
Figure 36. Europe Non-Insulin Therapies for Diabetes Market Share by Country (2016-2027)
Figure 37. Germany Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. France Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. U.K. Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Italy Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Russia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Nordic Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Asia-Pacific Non-Insulin Therapies for Diabetes Market Share by Type (2016-2027)
Figure 45. Asia-Pacific Non-Insulin Therapies for Diabetes Market Share by Application (2016-2027)
Figure 46. Asia-Pacific Non-Insulin Therapies for Diabetes Market Share by Region (2016-2027)
Figure 47. China Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Japan Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. South Korea Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Southeast Asia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. India Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Australia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Latin America Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Latin America Non-Insulin Therapies for Diabetes Market Share by Type (2016-2027)
Figure 55. Latin America Non-Insulin Therapies for Diabetes Market Share by Application (2016-2027)
Figure 56. Latin America Non-Insulin Therapies for Diabetes Market Share by Country (2016-2027)
Figure 57. Mexico Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Brazil Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Middle East & Africa Non-Insulin Therapies for Diabetes Market Share by Type (2016-2027)
Figure 61. Middle East & Africa Non-Insulin Therapies for Diabetes Market Share by Application (2016-2027)
Figure 62. Middle East & Africa Non-Insulin Therapies for Diabetes Market Share by Country (2016-2027)
Figure 63. Turkey Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 64. Saudi Arabia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 65. UAE Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 66. GSK Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 67. Eli Lilly Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 68. Sumitomo Dainippon Pharma Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 69. Intarcia Therapeutics Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 70. Servier Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 71. Pfizer Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 72. Merck Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 73. Dong-A Pharmaceutical Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 74. Luye Pharma Group Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 75. Eurofarma Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 76. Geropharm Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 77. Alkem Labs Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 78. SatRx Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 79. Jiangsu Hansoh Pharmaceutical Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 80. Novo Nordisk Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 81. Emisphere Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 82. Uni-Bio Science Group Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 83. Takeda Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 84. 3SBio Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 85. Jiangsu Hengrui Medicine Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021)
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed
世界の糖尿病用非インスリン療法市場 2021：企業別、地域別、種類・用途別 The Non-Insulin Therapies for Diabetes market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, tr…- 世界のジペプチジルペプチダーゼIV（DPP-IV）阻害剤市場 2021：企業別、地域別、種類・用途別 The Dipeptidyl Peptidase IV (DPP-IV) Inhibitors market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimiz…
- 世界の2型糖尿病治療薬市場規模・現状・予測（2021年-2027年） This Report focus on medications for type 2 diabetes. People with type 2 diabetes are often given medications including insulin to help manage their blood glucose levels. Most of these medications are in the form of tablets, but some are given by injection. Tablets or injections are intended to be u…
- 世界のTNF阻害剤市場規模・現状・予測（2021年-2027年） TNF (tumor necrosis factor) inhibitors are anti-inflammatory drugs. TNF inhibitors help to block the TNF alpha that occurs naturally in the body and causes inflammation. TNF drugs are used to reduce inflammation and stop disease progression by targeting the tumor necrosis factor, which is an inflamm…
- 世界の抗糖尿病薬市場規模・現状・予測（2021年-2027年） The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for…